EUROPEAN COMMISSION
DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY
Health systems, medical products and innovation
Medicines: policy, authorisation and monitoring
Brussels
SANTE.DDG1.B.5/
(2021)718650
The objective of the call was to touch base after the adoption of the strategy and see how
MsF can contribute to the consultation process.
MsF is interested in making contributions on the intellectual property (IP) Action plan
(supplementary protection certificate (SPC) evaluation). MsF is not in favor of SPCs as
they mainly target innovation-creating conditions that counter the affordability of
medicines. They are in favor of limiting protection periods especially were there has been
public investment in R&D.
Other areas of interest are antimicrobial resistance (AMR), Health and Emergency
Response Authority (HERA) and the PT presidency conference on access in April.
SANTE summarized the actions in the strategy and explained the timeframe of the
revision of the general pharmaceutical acts. It explained that input from MsF would be
most useful in written format at this stage as the policy choices are being developed. In
the second semester of 2021, the process will go into the public consultation phase where
discussions can take place with all stakeholders on the basis of more specific policy
options.
END
Participants: MsF:
Sante:
Commission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË - Tel. +32 22991111